Illumina, Nanosys, Paradigm | GenomeWeb

Illumina, Nanosys, Paradigm

Premium

Illumina Revenues Up

Illumina reported increased revenues for the first quarter last week, amid nearly flat net losses.

The San Diego genotyping and oligonucleotide company’s revenues for the quarter totaled $4.3 million, up from $1.3 million for the year-ago quarter. Net losses totaled $9.0 million, up from $8.7 million for the first quarter of 2002. Research and development expenses were $5.7 million, from $7.1 million in Q1 2002.

 

Nanosys GET New Funders in $30M Series B

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.